Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Descriptor ID |
D009364
|
MeSH Number(s) |
C04.697.655 C23.550.727.655
|
Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 0 | 2 | 2 | 1982 | 1 | 4 | 5 | 1983 | 0 | 3 | 3 | 1984 | 2 | 6 | 8 | 1985 | 0 | 2 | 2 | 1986 | 3 | 5 | 8 | 1987 | 1 | 1 | 2 | 1988 | 4 | 4 | 8 | 1989 | 2 | 7 | 9 | 1990 | 2 | 3 | 5 | 1991 | 2 | 5 | 7 | 1992 | 1 | 4 | 5 | 1993 | 1 | 6 | 7 | 1994 | 2 | 3 | 5 | 1995 | 3 | 5 | 8 | 1996 | 8 | 9 | 17 | 1997 | 3 | 8 | 11 | 1998 | 0 | 9 | 9 | 1999 | 6 | 5 | 11 | 2000 | 6 | 13 | 19 | 2001 | 3 | 10 | 13 | 2002 | 4 | 5 | 9 | 2003 | 9 | 9 | 18 | 2004 | 11 | 11 | 22 | 2005 | 6 | 17 | 23 | 2006 | 21 | 11 | 32 | 2007 | 12 | 16 | 28 | 2008 | 6 | 18 | 24 | 2009 | 16 | 13 | 29 | 2010 | 19 | 21 | 40 | 2011 | 14 | 8 | 22 | 2012 | 17 | 11 | 28 | 2013 | 18 | 20 | 38 | 2014 | 19 | 16 | 35 | 2015 | 21 | 17 | 38 | 2016 | 27 | 17 | 44 | 2017 | 26 | 7 | 33 | 2018 | 19 | 21 | 40 | 2019 | 31 | 23 | 54 | 2020 | 20 | 29 | 49 | 2021 | 18 | 19 | 37 | 2022 | 3 | 10 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Li S, Zeng W, Ni X, Zhou Y, Stackpole ML, Noor ZS, Yuan Z, Neal A, Memarzadeh S, Garon EB, Dubinett SM, Li W, Zhou XJ. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clin Cancer Res. 2022 May 02; 28(9):1841-1853.
-
Kindler HL, Novello S, Bearz A, Ceresoli GL, Aerts JGJV, Spicer J, Taylor P, Nackaerts K, Greystoke A, Jennens R, Calabrò L, Burgers JA, Santoro A, Cedrés S, Serwatowski P, Ponce S, Van Meerbeeck JP, Nowak AK, Blumenschein G, Siegel JM, Kasten L, Köchert K, Walter AO, Childs BH, Elbi C, Hassan R, Fennell DA. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 Apr; 23(4):540-552.
-
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 04 30; 399(10336):1718-1729.
-
Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 Apr; 28(4):735-742.
-
Semina SE, Pal P, Kansara NS, Huggins RJ, Alarid ET, Greene GL, Frasor J. Selective pressure of endocrine therapy activates the integrated stress response through NF?B signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Res. 2022 Mar 09; 24(1):19.
-
Jeong AR, Forbes K, Orosco RK, Cohen EEW. Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. J Otolaryngol Head Neck Surg. 2022 Feb 05; 51(1):5.
-
Van Blarigan EL, Ou FS, Bainter TM, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Hantel A, Benson AB, Atienza D, Messino M, Kindler HL, Venook AP, Ogino S, Sanoff HK, Giovannucci EL, Ng K, Meyerhardt JA. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Netw Open. 2022 02 01; 5(2):e220145.
-
Ozaki K, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Abe H, Ushiku T, Ishihara S. Impact of the viability assessment of lateral lymph node metastasis in rectal cancer after neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2022 Feb; 37(2):467-473.
-
Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
-
Cheng E, Ou FS, Ma C, Spiegelman D, Zhang S, Zhou X, Bainter TM, Saltz LB, Niedzwiecki D, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Brown JC, Ng K, Gross CP, Meyerhardt JA, Fuchs CS. Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). J Clin Oncol. 2022 03 01; 40(7):740-751.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|